SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-209920
Filing Date
2024-08-29
Accepted
2024-08-29 16:16:01
Documents
14
Period of Report
2024-08-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d890088d8k.htm   iXBRL 8-K 24804
2 EX-99.1 d890088dex991.htm EX-99.1 69736
  Complete submission text file 0001193125-24-209920.txt   229626

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA artv-20240829.xsd EX-101.SCH 2878
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE artv-20240829_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE artv-20240829_pre.xml EX-101.PRE 11726
16 EXTRACTED XBRL INSTANCE DOCUMENT d890088d8k_htm.xml XML 3776
Mailing Address 5505 MOREHOUSE DRIVE SAN DIEGO CA 92121
Business Address 5505 MOREHOUSE DRIVE SAN DIEGO CA 92121 (858) 267-4467
Artiva Biotherapeutics, Inc. (Filer) CIK: 0001817241 (see all company filings)

IRS No.: 863614316 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42179 | Film No.: 241263895
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)